Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1239152 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D | |
| SCHEMBL29808940 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D | |
| SCHEMBL14490666 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D | |
| SCHEMBL1239150 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D | |
| SCHEMBL1134242 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D | |
| SCHEMBL1643076 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D | |
| SCHEMBL8309860 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D | |
| SCHEMBL29809038 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D | |
| SCHEMBL6767234 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D | |
| SCHEMBL1239149 | 1.00 | KDM1A (0.47) | KDM1AHTR2AANPEPSIGMAR1GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560482-B2 | Inhibitors of plasmepsins | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-07-14 | — | — | US | claimed |
| US-20050037953-A1 | Inhibitors of plasmepsins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-02-17 | — | — | US | claimed |
| US-6171832-B1 | FERMENTING STARTING MATERIAL IN CULTURE, RECOVERING PRODUCT; BY PRODUCT INHIBITION; CHEMICAL INTERMEDIATE FOR SYNTHESIS OF INDINAVIR, A POTENT HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITOR | MERCK & CO., INC. | 2001-01-09 | — | — | US | claimed |
| US-5871981-A | COMPOUNDS FOR TREATMENT OF AIDS | MERCK & CO., INC. (US) | 1999-02-16 | — | — | US | claimed |
| US-5858737-A | INCUBATING MIXTURE OF INDENE AND PSEUDOMONAS PUTIDA TO GIVE DESIRED ISOMER OF INDANDIOL | MERCK & CO., INC. (US) | 1999-01-12 | — | — | US | claimed |
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| US-20110086860-A1 | COMPOUND | KIMURA TEIJI | 2011-04-14 | — | — | US | disclosed |
| US-7880009-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; (E)-N-biphenyl-3-ylmethyl-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)acrylamide for example; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-2261218-A2 | Process for preparing phenyl-, pyridinyl- or pyrimidinyl-substituted imidazoles | Eisai R&D Management Co., Ltd. (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-7687640-B2 | Cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-7667041-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-12 | — | — | US | disclosed |
| WO-1998006866-A1 | CONVERSION OF INDENE TO (1S)-AMINO-(2R)-INDANOL FREE OF ANY STEREOISOMER, BY COMBINATION OF DIOXYGENASE BIOCONVERSION AND CHEMICAL STEPS | MERCK & CO., INC. (US) | 1998-02-19 | — | — | WO | disclosed |
| WO-1998006866-A1 | CONVERSION OF INDENE TO (1S)-AMINO-(2R)-INDANOL FREE OF ANY STEREOISOMER, BY COMBINATION OF DIOXYGENASE BIOCONVERSION AND CHEMICAL STEPS | MERCK & CO., INC. (US) | 1998-02-19 | — | — | WO | disclosed |
| US-5677469-A | PREPARING MIXTURE OF CHIRAL ACID AND ENANTIOMER OF AMINOINDANOL IN SOLVENT, SEPARATING DIASTEREOMERIC SALT, RECOVERING CHIRAL ACID | SEPRACOR, INC. (US) | 1997-10-14 | — | — | US | disclosed |
| WO-1997000966-A1 | CONVERSION OF INDENE TO (1S)-AMINO-(2R)-INDANOL FREE OF ANY STEREOISOMER, BY COMBINATION OF DIOXYGENASE BIOCONVERSION AND CHEMICAL STEPS | MERCK & CO., INC. (US) | 1997-01-09 | — | — | WO | disclosed |
| WO-1997000966-A1 | CONVERSION OF INDENE TO (1S)-AMINO-(2R)-INDANOL FREE OF ANY STEREOISOMER, BY COMBINATION OF DIOXYGENASE BIOCONVERSION AND CHEMICAL STEPS | MERCK & CO., INC. (US) | 1997-01-09 | — | — | WO | disclosed |
| US-5489710-A | AMINATION BY MIXING WITH NITRILE SOLVENT, ACIDIFICATION AND HYDROLYZING WITH WATER | MERCK & CO., INC. (US) | 1996-02-06 | — | — | US | disclosed |
| US-5449830-A | Enzyme inhibitors for protease encoded for HIV | MARCK & CO., INC. (US) | 1995-09-12 | — | — | US | disclosed |
| EP-0144235-A2 | N6-(1- and 2-benzocycloalkyl) adenosines, pharmaceutical compositions comprising the same and a process for the production thereof | WARNER-LAMBERT COMPANY (US) | 1985-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086860-A1 | COMPOUND | ARRB1, NR3C2, ADRA2C | KDM1A 1903/4885HTR2A 695/4885ANPEP 2755/4885 |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | APP, PSEN1, BACE1 | KDM1A 823/4885HTR2A 373/4885ANPEP 1945/4885 |
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | GRM7, GRIN2B, GRM1 | KDM1A 1761/4885HTR2A 155/4885ANPEP 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.